Abstract: Crizotinib is a selective ATP-competitive inhibitor of anaplastic lymphoma kinase(ALK), hepatocyte growth factor receptor(c-Met/HGFR) tyrosine kinases and their oncogenic variants. In PROFILE 1001 and PROFILE 1005 clinical trials, the response rate of crizotinib is 50%~60% for non-small cell lung cancer(NSCLC) patients with ALK rearrangement. Most of the adverse events are grade 1~2. Vysis ALK breakapart FISH probe kit is the standard diagnostic test to detect ALK-rearrangement. ALK-rearrangement is more often seen in never/light smokers with lung adenocarcinomas. The mechanism of crizotinib resistance is complicated.

Key words: crizotinib, anaplastic lymphoma kinase gene rearrangement, non-small cell lung cancer